MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$6,590K
Proceeds from short-term
convertible debt
$4,375K
Net cash provided by
financing activities
$7,565K
Canceled cashflow
$3,400K
Net decrease in cash
and cash...
-$9,091K
Canceled cashflow
$7,565K
Stock-based compensation
expense
$2,686K
Change in fair value of
convertible debt
-$1,773K
Non-cash discount on
convertible debt
$625K
Amortization of operating
lease right-of-use...
$588K
Depreciation expense
$244K
Other current assets
-$18K
Repayments of short-term
convertible debt
$3,400K
Net cash used in
operating activities
-$16,394K
Canceled cashflow
$5,934K
Net cash used in
investing activities
-$262K
Net loss
-$18,646K
Accounts payable and
accrued expenses
-$1,502K
Prepaid expenses
$1,230K
Operating lease liability
-$550K
Change in fair value of
sepa put option...
$352K
Other assets
$48K
Purchases of property and
equipment
$262K
Back
Back
Cash Flow
source: myfinsight.com
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)